Innovative Cancer Medicines

active

ACTIVE SINCE: 2022

SGDS CONTRIBUTING TO:

MEMBER COMPANIES:

Academia or research institute 1

Global NGOs 1

BMS is participating in the “Innovative Cancer Medicines” partnership along with the Parker Institute for Cancer Immunotherapy, the Clinton Health Access
Initiative, and another pharmaceutical company.
The goal of the initiative is to develop an approach that explores sustainable and effective administration of innovative therapies for the treatment of cancer in LMICs. Through the initiative, demonstration projects are being planned in sub-Saharan Africa that focus on operational excellence.
The initial pilots are planned for Uganda and Nigeria where patients will be enrolled in the demonstration projects.
Local stakeholders in each country have selected the respective indications based on local population needs. In addition, the indications that are finalized will be those with approvals in the United States and/or Europe.
BMS has committed to: providing funding, nab-paclitaxel and/or nivolumab free of charge as needed per indication, and other assistance such as safety training.
The pilots are projected to start in 2023 and BMS will continue to actively engage with partners to ensure that the demonstration projects progress as planned.

SDG 3: Good Health and Wellbeing

SDG 17: Partnerships for the Goals

Academia or research institute

Parker Institute for Cancer Immunotherapy

Global NGOs

Clinton Health Access Initiative (CHAI)